Proactive Investors - Run By Investors For Investors

Cellmid has significant new findings on midkine published in leading medical journal

Recently published study findings show Cellmid’s midkine antibodies prevented heart muscle damage and preserved function.
human heart
Cellmid now plans to validate further findings

Cellmid Ltd (ASX:CDY) has revealed that the prestigious Journal of Experimental Medicine has published a significant study showing for the first time that midkine, around which the company holds extensive intellectual property rights, promotes cardiac muscle inflammation associated with the occasionally fatal autoimmune disease, myocarditis.

Cellmid’s midkine antibodies prevent cardiac muscle damage due to rampant inflammation, thereby reducing fibrosis and preserving cardiac function.

READ: Cellmid becomes profitable in December after achieving record quarterly sales

The paper by Cellmid collaborators Dr Ludwig Weckbach and Professor Barbara Walzog describes how midkine is key to the inflammatory processes of myocarditis leading to cardiomyopathy and end-stage heart failure.

As the holder of the most significant intellectual property assets around midkine globally, the publication provides Cellmid with exposure to and a strong platform for partnerships.

Important further studies planned

The findings of midkine’s role in autoimmune myocarditis may be relevant to the dangerous side effects of new blockbuster cancer drugs that boost the immune system to combat tumours.

By taking the breaks off the immune system, checkpoint inhibitors often cause immune related adverse events that can develop rapidly and, in the case of autoimmune myocarditis, are fatal in about one to four percent of all patients treated with checkpoint inhibitors.

Cellmid head of R&D Dr Graham Robertson said: “The potential of Cellmid’s midkine antibodies to alleviate the heart failure experienced by cancer patients may lead to deploying our midkine assets as an adjunct therapy in oncology to work alongside immuno-oncology drugs.”

READ: Cellmid builds IP for midkine portfolio with new patents

The latest findings and planned future studies support the therapeutic application of Cellmid’s midkine antibodies in the treatment of myocarditis, including myocarditis resulting from injury to the myocardium by toxins, therapeutic agents and other drugs, infectious agents and other autoimmune diseases/conditions.

View full CDY profile View Profile

Cellmid Ltd Timeline

Related Articles

scientist in laboratory
May 24 2019
Here we take a closer look at healthcare investor NetScientific PLC (LON:NSCI)
parsortix
February 01 2019
The cancer detection device is on track to finish a key clinical study in the first quarter of 2019, but in the meantime, it has shown promise in detecting abnormalities in unborn children
A paper rocket is ready to launch on a surgeon's scissors
March 28 2019
The company hopes to improve its share price with ADAPT technology successes.

© Proactive Investors 2019

Proactive Investors Limited, trading as “Proactiveinvestors United Kingdom”, is Authorised and regulated by the Financial Conduct Authority.
Registered in England with Company Registration number 05639690. Group VAT registration number 872070825 FCA Registration number 559082. You can contact us here.

Market Indices, Commodities and Regulatory News Headlines copyright © Morningstar. Data delayed 15 minutes unless otherwise indicated. Terms of use